{
    "Patient": {
        "Name": "John Parker",
        "DOB": "1960-08-17",
        "Sex": "Female",
        "Caseno": "6467",
        "Diagnosis": "Medullary thyroid cancer",
        "Physician": "Dr. Brenda Munoz"
    },
    "specimen information": {
        "primary_tumor_site": "Thyroid",
        "specimen_site": "Thyroid gland",
        "specimen_ID": "8001",
        "CollectedDate": "2024-04-09",
        "ReceivedDate": "2024-04-09",
        "Pathological Diagnosis": "Left breast, central, 12:00, suspicious mass, 12-gauge core needle biopsy: Infiltrating moderately-differentiated mammary carcinoma, grade 2, Nottingham score 6 (architectural grade 3, nuclear grade 2, mitotic figures 1).",
        "Dissection Information": "Molecular testing of this specimen was performed after harvesting of targeted tissues with an approved manual microdissection technique. Candidate slides were examined under a microscope and areas containing tumor cells (and separately normal cells, when necessary for testing) were circled. A laboratory technician harvested targeted tissues for extraction from the marked areas using a dissection microscope."
    },
    "Results with Therapy association": [
        {
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 3+, 100%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine",
                "therapy",
                "everolimus"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Result": "Positive | 2+, 95%",
            "Therapy association": [
                "BENEFIT",
                "abemaciclib",
                "palbociclib",
                "ribociclib",
                "endocrine therapy"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "TMB",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "17 m/Mb High",
            "Therapy association": [
                "BENEFIT",
                "pembrolizumab"
            ],
            "Biomarker_level": "level 2"
        },
        {
            "Biomarker": "ERBB2",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative | 0",
            "Therapy association": [
                "LACK OF BENEFT",
                "trastuzumab",
                "ado-trastuzumab emtansine",
                "pertuzumab",
                "fam-trastuzumab deruxtecan-nxki",
                "lapatinib",
                "neratinib",
                "tucatinib"
            ],
            "Biomarker_level": "level 1"
        }
    ],
    "Relevant Biomarkers": [
        {
            "BioMarker": "CHD6",
            "Method": "Seq",
            "Analyte": "DNA-Tumor",
            "Result": "Stable"
        },
        {
            "BioMarker": "PTPN11",
            "Method": "Seq",
            "Analyte": "DNA-Tumor",
            "Result": "Stable"
        },
        {
            "BioMarker": "NRAS",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Fusion not detected"
        },
        {
            "BioMarker": "HBA2",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Fusion not detected"
        },
        {
            "BioMarker": "CALR",
            "Method": "Seq",
            "Analyte": "RNA-Tumor",
            "Result": "Stable"
        },
        {
            "BioMarker": "Mismatch repair status",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 2+, 64%"
        },
        {
            "BioMarker": "ER",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 1+, 10%"
        },
        {
            "BioMarker": "AR",
            "Method": "IHC",
            "Analyte": "Protien",
            "Result": "Negative| 1+, 83%"
        }
    ],
    "Genomic Signatures": [
        {
            "BioMarker": "Microsatellite instability",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High"
        },
        {
            "BioMarker": "Tumor mutational burden",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "17 mutations/Mb High"
        },
        {
            "BioMarker": "Genomic loss of heterozygosity (LOH)",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Result": "High - 39% of tested genomic segments exhibit LOH"
        }
    ],
    "Genes Tested with Pathogenic Alterations": [
        {
            "Gene": "EZH2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Benign",
            "Protien Alteration": "p.L239R",
            "Exon": 12,
            "DNA Alteration": "c.716T>G",
            "Allele Frequency %": "3.69"
        },
        {
            "Gene": "CSF3R",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Pathogenic",
            "Protien Alteration": "p.N713_A714insKGKGGG",
            "Exon": 20,
            "DNA Alteration": "c.1924A>C",
            "Allele Frequency %": "1.0"
        },
        {
            "Gene": "PTCH1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Pathogenic",
            "Protien Alteration": "p.E17K",
            "Exon": 2,
            "DNA Alteration": "c.49G>A",
            "Allele Frequency %": "26.93"
        },
        {
            "Gene": "PRKCA",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Likely Pathogenic",
            "Protien Alteration": "p.S346P",
            "Exon": 13,
            "DNA Alteration": "G",
            "Allele Frequency %": "23.11"
        },
        {
            "Gene": "JAK2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Pathogenic",
            "Protien Alteration": "p.F332V",
            "Exon": 2,
            "DNA Alteration": "G",
            "Allele Frequency %": "12.13"
        },
        {
            "Gene": "RNF43",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Benign",
            "Protien Alteration": "p.V842I",
            "Exon": 6,
            "DNA Alteration": "c.2325_2326ins12",
            "Allele Frequency %": "9.83"
        }
    ],
    "Gene variants of unknown significance": [
        {
            "Gene": "HSD3B1",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.L367fs*46",
            "Exon": 2,
            "DNA Alteration": "c.1092_1143del52",
            "Allele Frequency %": "25.53"
        },
        {
            "Gene": "EGFR",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.E122K",
            "Exon": 9,
            "DNA Alteration": "c.19G>A",
            "Allele Frequency %": "3.96"
        },
        {
            "Gene": "H3.3",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.S163P",
            "Exon": 12,
            "DNA Alteration": "c.487T>C",
            "Allele Frequency %": "19.22"
        },
        {
            "Gene": "FOXL2",
            "Method": "Seq",
            "Analyte": "DNA tumor",
            "Variant Interpretation": "Variant of uncertain significance",
            "Protien Alteration": "p.D463H",
            "Exon": 10,
            "DNA Alteration": "c.1387G>C",
            "Allele Frequency %": "14.75"
        }
    ],
    "Immunohistochemistry results": [
        {
            "Biomarker": "ER",
            "Result": "Negative| 1+, 96%"
        },
        {
            "Biomarker": "ERBB2",
            "Result": "Positive| 3+, 6%"
        },
        {
            "Biomarker": "PTEN",
            "Result": "Negative| 3+, 42%"
        },
        {
            "Biomarker": "MLH1",
            "Result": "Negative| 3+, 10%"
        },
        {
            "Biomarker": "MSH6",
            "Result": "Negative| 3+, 86%"
        },
        {
            "Biomarker": "MSH2",
            "Result": "Negative| 1+, 32%"
        },
        {
            "Biomarker": "PR",
            "Result": "Negative| 1+, 7%"
        },
        {
            "Biomarker": "AR",
            "Result": "Negative| 1+, 76%"
        }
    ],
    "Genes Tested with indeterminate results": [
        "HBA2",
        "EGFR",
        "MSH2",
        "NTRK1",
        "MYD88"
    ],
    "Chemotherapy clinical trials": [
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "ER",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti hormonal therapy",
            "Biomarker": "PR",
            "Method": "IHC",
            "Analyte": "protein",
            "Investigational agents": [
                "anastrazole",
                "letrozole",
                "exemestane",
                "fulvestrant",
                "tamoxifen",
                "goserelin",
                "leuprolide"
            ]
        },
        {
            "Drug class": "Anti inflammatory agents",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "aspirin"
            ]
        }
    ],
    "Targeted therapy clinical trials": [
        {
            "Drug class": "Akt inhibitors",
            "Biomarker": "ARID1A",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "MK-2206",
                "ipataserib"
            ]
        },
        {
            "Drug class": "immunomodulatory agents",
            "Biomarker": "TMB",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "avelumab",
                "atezolizumab",
                "durvalumab",
                "ipilimumab",
                "nivolumab",
                "pembrolizumab"
            ]
        },
        {
            "Drug class": "PARP inhibitors",
            "Biomarker": "NBN",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "BGB-290",
                "BMN-673",
                "olaparib",
                "rucaparib",
                "talazoparib"
            ]
        },
        {
            "Drug class": "Akt/mTor inhibitors",
            "Biomarker": "PIK3CA",
            "Method": "NGS",
            "Analyte": "DNA tumor",
            "Investigational agents": [
                "AZD5363",
                "BYL719",
                "MK-2206",
                "ipataserib",
                "everolimus",
                "temsirolimus"
            ]
        }
    ]
}